Orilissa
(elagolix)ApprovedSmall molecule
AbbVieElagolix is used to treat moderate to severe pain caused by endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus. It works by reducing the hormones that cause this tissue to grow and cause pain.[2] Orilissa is currently approved and in use across 5 indications[4].[1]
Orilissa is one of 126 small molecule programs targeting Menopause. It is currently in Approved.
5
Indications
32
Total Trials
4
Active Trials
125
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
9
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
146 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Geodon
PfizerApproved
Cardene
Sun Pharmaceutical Industries, Inc.Approved
Primacor
SanofiApproved
Orilissa
AbbVieApproved
Camzyos
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Midamor
PPadagis LLC
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Approved
Colcrys
Jazz PharmaceuticalsPhase 3
Pelacarsen
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Endometriosis16 trials
Show 13 more trials
Uterine Fibroid7 trials
Women1 trial
Polycystic Ovary Syndrome1 trial
6 more indications
Menstrual Cycle1 trial
Adenoma1 trial
Regulatory
FDA Approval Timeline[5]
Jul 23, 2018
ORILISSA
NDA NDA210450
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Orilissa drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for elagolix. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]